Tolerability Study of Investigational Agent, ARRY-142886, in Patients With Cancer - Tabular View

Home

Study Topics

Glossary


	Full Text View


	Tabular View


	Contacts and Locations


	No Study Results Posted


	Related Studies

Tolerability Study of Investigational Agent, ARRY-142886, in Patients With Cancer

This study is ongoing, but not recruiting participants.

Study NCT00085787. Last updated on July 12, 2007. Information provided by Array BioPharma

This Tabular View shows the required WHO registration data elements as marked by ^†

Descriptive Information Fields
Brief Title ^†	Tolerability Study of Investigational Agent, ARRY-142886, in Patients With Cancer
Official Title ^†	A Phase I, Open-Label, Multiple Dose Study to Assess the Tolerability, Pharmacokinetics and Pharmacodynamics of ARRY-142886 Given on a Daily Oral Regime in Subjects With Advanced Solid Malignancies
Brief Summary	The purpose of this study is to assess the tolerability of ARRY-142886 in patients with advanced solid malignancies that have failed standard therapy or for whom no standard therapy exists and determine the maximum tolerated dose as defined by significant dose limiting toxicity.
Detailed Description
Study Phase	Phase I
Study Type ^†	Interventional
Study Design ^†	Treatment, Open Label, Pharmacokinetics/Dynamics Study
Primary Outcome Measure ^†
Secondary Outcome Measure ^†
Condition ^†	Cancer
Intervention ^†	Drug: ARRY-142886
MEDLINE PMIDs
Links

Recruitment Information Fields
Recruitment Status ^†	Active, not recruiting
Enrollment ^†
Start Date ^†
Completion Date
Eligibility Criteria ^†	Inclusion Criteria: Confirmed solid tumor which is refractory to standard therapies At least 18 years old Ambulatory with ECOG status of 0-2 Life expectancy of greater than or equal to 3 months Exclusion Criteria: Brain metastases Use of investigational medication or device within 30 days Major surgery within 30 days Radiotherapy or chemotherapy within 21 days Pregnant or lactating Known positive for HIV
Gender	Both
Ages	18 Years and older
Accepts Healthy Volunteers	No
Contacts ^††
Location Countries ^†	United States

Administrative Information Fields
NCT ID ^†	NCT00085787
Organization ID	ARRY-0401
Secondary IDs ^††
Study Sponsor ^†	Array BioPharma
Collaborators ^††
Investigators ^†
Information Provided By	Array BioPharma
Verification Date	July 2007
First Received Date ^†	June 14, 2004
Last Updated Date	July 12, 2007

^† Required WHO trial registration data element.
^†† WHO trial registration data element that is required only if it exists.